Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) EBIT (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of EBIT readings, the most recent being -$10.5 million for Q1 2026.

  • Quarterly EBIT fell 28.71% to -$10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$36.7 million through Mar 2026, down 505.69% year-over-year, with the annual reading at -$34.4 million for FY2025, 839.3% down from the prior year.
  • EBIT hit -$10.5 million in Q1 2026 for DiaMedica Therapeutics, down from -$9.2 million in the prior quarter.
  • Across five years, EBIT topped out at $14.6 million in Q4 2024 and bottomed at -$10.5 million in Q1 2026.
  • Average EBIT over 5 years is -$4.9 million, with a median of -$5.6 million recorded in 2024.
  • The largest annual shift saw EBIT skyrocketed 349.66% in 2024 before it plummeted 163.1% in 2025.
  • DiaMedica Therapeutics' EBIT stood at -$4.0 million in 2022, then crashed by 47.19% to -$5.8 million in 2023, then skyrocketed by 349.66% to $14.6 million in 2024, then plummeted by 163.1% to -$9.2 million in 2025, then decreased by 13.77% to -$10.5 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's EBIT are -$10.5 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.0 million (Q3 2025).